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Objectives: Presently, linaclotide is the only EMA approved therapy indicated for 
the treatment of irritable bowel syndrome with constipation (IBS-C). This study 
sought to determine the cost-effectiveness of linaclotide compared to antidepres-
sants for the treatment of adults with moderate to severe IBS-C who have previ-
ously received antispasmodics and/or laxatives from the perspective of the Scottish 
National Health System (NHS). MethOds: A Markov model was created to estimate 
costs and QALYs over a 5-year time horizon from the perspective of NHS Scotland. 
Health states were based on treatment satisfaction (satisfied, moderately satisfied, 
not satisfied) and death. Transitions between states were based on satisfaction data 
from the linaclotide pivotal studies (MCP-103-302 and LIN-MD-31) and Scottish 
general all-cause mortality statistics. Treatment costs were calculated from the 
British National Formulary. NHS resource use and disease-related costs for each 
health state were estimated from Scottish clinician interviews in combination with 
NHS Reference costs. Quality of life was based on EQ-5D data collected from the 
pivotal studies. Costs and QALYs were discounted at 3.5% per annum. Uncertainty 
was explored through extensive deterministic and probabilistic sensitivity analy-
ses. Results: Over a 5-year time horizon, the additional costs and QALYs with 
linaclotide were £659 and 0.089, resulting in an incremental cost-effectiveness ratio 
of £7,370 per QALY versus antidepressants. Results were most sensitive to health 
state transitions probabilities, NHS resource use assumptions and health state 
utilities. Threshold analyses showed that the effectiveness of linaclotide would 
have to be at least 11% lower than the base case to exceed a willingness-to-pay 
threshold (WTP) of £20,000 per QALY. Based on the probabilistic sensitivity analysis, 
the likelihood that linaclotide was cost-effective at a WTP of £20,000 per QALY was 
74%. cOnclusiOns: Linaclotide is a cost-effective treatment for adults with mod-
erate to severe IBS-C who have previously received antispasmodics and/or laxatives.
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Objectives: To assess the cost-effectiveness of treating chronic HCV infection 
(genotype 1) with currently available telaprevir+pegylated interferon alpha/ribavirin 
(TPR) compared to waiting for new regimens with improved efficacy (hypothetical 
treatment assumed) currently in development from the French health care perspec-
tive. MethOds: A Markov model tracked the adult naïve HCV+ French population 
over a lifetime horizon. Model health-states are defined by METAVIR fibrosis stage 
(F0-F4) and complications of advanced HCV (decompensated cirrhosis, hepatocel-
lular carcinoma, liver transplant, and death). During each 1-year cycle, individu-
als may remain in the current health-state, respond to treatment or progress, at 
probabilities determined by disease status, age at infection, current age, gender, 
and treatment received. Individuals were eligible for treatment in F2-F4. Transition 
probabilities, treatment efficacy, health-state utilities, resource utilization and costs 
were derived from published literature and standard French sources. The efficacy 
of a new hypothetical treatment regimen was based on currently published results; 
cost for the new treatment was assumed at € 50,000 for a full treatment (excluding 
PR backbone). Results: A treatment lag of 1, 2, and 3 years resulted in 142,777 indi-
viduals, 140,417 individuals, and 137,930 individuals being treated by the new regi-
men, respectively, versus 145,010 with immediate TPR treatment. The new treatment 
option resulted in additional life years saved (range 11,230-27,536), QALYs gained 
(range 12,528-29,359), and prevented more HCV-related deaths (range 3,839-5,756). 
Total costs incurred were higher for the new regimen versus TPR, from the health 
care perspective. ICERs were € 58,294.49/QALY, € 73,295.59/QALY, and € 107,403.02/
QALY gained for a 1, 2, and 3 year treatment lag, respectively. cOnclusiOns: These 
findings suggest waiting for new regimens currently in development should not be 
the most efficient choice to be considered by French Health care system. Waiting 
for new treatments should yield better clinical outcomes, but with higher costs and 
ICERS that may be challenging for the payer.
PGI29
Crohn’s dIsEasE: an EConomIC assEssmEnt of bIoLoGICaL druGs In 
ItaLy
Cicchetti A.1, Gasbarrini A.2, Ruggeri M.1
1Università Cattolica del Sacro Cuore, Rome, Italy, 2Università Cattolica del Sacro Cuore, Rome, 
Italy, Italy
Objectives: This study had a dual objective: verify the improvements in qual-
ity of life (QoL) due to biological drugs administration and evaluate their cost-
effeffectiveness versus the standard steroid-based therapy in Crohn’s Disease 
(CD). High-cost biological drugs’ efficacy is well-established, but they still lack of 
cost-effectiveness studies. MethOds: A survey was prepared with clinicians and 
pharmacoeconomists and administered in 9 centers in Italy. The questionnaire 
was set up to detect QoL through a Visual Analogue Scale and EQ-5D and to assess 
patients’ profile (age, gender, job) and clinical features (time-to-first diagnosis, cur-
rent and at-diagnosis Montreal classification, current and at-diagnosis treatments, 
past surgical procedures, hospitalizations). Collected data were then used in a sta-
tistical regression model and an economic assessment complete of probabilistic 
sensitivity analysis was performed comparing costs and utilities of the considered 
treatments. Results: A total of 348 questionnaires were collected, giving back a 
Objectives: Establish the potential resource and cost savings from using ePTFE 
covered stent-grafts configured for TIPS (SG) compared to bare metal stents (BMS). 
Most centres have adopted SGs to treat portal hypertension because of their 
reduced re-intervention rates, elimination of regular monitoring of patency and 
improved survival. However there is no published economic analysis identifying 
the related cost consequences. Understanding the improved efficiencies is essen-
tial in the current financial environment. MethOds: A Markov economic model 
was developed to measure the incremental costs of the initial procedure and 
re-interventions with SG compared to BMS. Re-intervention procedures included 
angioplasty (67%), introducing a balloon expandable stent (22%) or a second stent 
(10%). The adverse events were hepatic encephalopathy and clinical relapse. 
Clinical data came mainly from a published RCT (Bureau 2007), whilst health care 
costs were from UK national databases. Results: Compared to BMS, using SG in 
TIPS resulted in a cost saving of over £1,150 per patient over 2 years. Modelling 100 
patients, compared to BMS, the SG cohort had 25 fewer re-interventions including 
angioplasties, saving 41 hours staff time in theatre and 16 inpatient days; with 
fewer cases of encephalopathy (16), recurrent ascites (8), variceal bleeds (5) and a 
markedly reduced mortality (13). cOnclusiOns: The model showed that ePTFE 
covered stent-grafts configured for TIPS reduced mortality and re-interventions, 
saved theatre time and bed-days, and reduced overall costs despite the higher 
initial device cost.
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Objectives: In 2011 EMA approved Boceprevir and Telaprevir with PegIFN and 
Ribavirin for the treatment of Genotype 1 Chronic Hepatitis C patients. In 2013 
the Greek and other European HCV Guidelines recommend treatment alloca-
tion in G1 naïve patients according to the IL28B genotype or the RVR profile. 
Local studies indicate that the IL28B-CC and the RVR (+) rates are approximately 
30%. The objective of this study was to implement this guidance and examine 
whether triple therapy with PegIFNa-2a+RBV and the two protease inhibitors, 
Boceprevir or Telaprevir, constitutes a cost-saving option for the treatment of 
naïve G1 patients in the Greek health care setting. MethOds: For the needs 
of this analysis, a cost-consequence model was utilized, to compare the costs 
incurred when: i) patients with IL28B CC aplotype (30%) were treated with SoC 
(PegIFN alfa-2a + RBV) and patients with IL28B non-CC aplotypes (70%) were 
treated with triple therapy and ii) all patients are treated with triple therapy. 
The economic inputs are based on official and publically available sources while 
the clinical inputs are taken from published clinical trial results. The number of 
patients treated per year was provided by local bibliography. Results: The total 
cost to treat 509 naïve patients with triple therapy was € 13,8 million compared to 
€ 10.9 million to treat based on IL28B allocation, maintaining the same SVR rate 
of 70% for either of the treatment strategies. cOnclusiOns: This personalized 
approach based on a baseline predictor of response such as the IL28B profile was 
proven to be a cost-saving resource allocation choice compared to the option 
of treating all treatment naive patients with triple therapy, providing SVR rates 
of 70% and a constrain of cost for the Greek health care system of € 2,9 million/
year (aprox.25%).
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Objectives: To assess the cost-effectiveness of treating HCV infection (geno-
type 1) with telaprevir/pegylated interferon alpha/ribavirin (TPR) at METAVIR 
fibrosis stage F2 (“early”) versus delaying treatment until progression to F3 
(“delayed”) from the French health care perspective. MethOds: A Markov 
model tracked the HCV+ French population aged 40+ over a lifetime horizon to 
compare outcomes of early versus delayed treatment. Model health states are 
defined by fibrosis stage (F0-F4) and complications of advanced HCV includ-
ing decompensated cirrhosis, hepatocellular carcinoma, liver transplant, and 
death. During each 1-year cycle, individuals may remain in the current health 
state, respond to treatment or progress, at probabilities determined by disease 
status, age at infection, current age, gender, and treatment received. Transition 
probabilities, treatment efficacy, health-state utilities, resource utilization and 
costs were derived from published literature and standard French sources. Costs 
and outcomes were discounted at 4.0% for 30 years and 2% thereafter. Cost-
effectiveness was assessed as incremental cost per life year gained (LYG) and 
QALY gained. Results: An estimated 203,644 French residents aged 40+ years 
are diagnosed with HCV in 2013. Treating with TPR at F2 versus F3 is projected 
to result in 135,240 versus 113,728 individuals treated, at an incremental life-
time cost of € 654.65M from the French health care perspective. Early treatment 
avoided 2,205 HCV-related deaths and saved 11,384 life-years, and 17,599 QALYs, 
at a cost of € 57,506/LYG and € 37,197/QALY gained. Results are most sensitive to 
efficacy parameters, time horizon, and discount rates and least sensitive to diag-
nosis and treatment parameters. cOnclusiOns: Treating HCV-infected indi-
viduals at F2 is expected to results in better clinical outcomes but at higher cost 
compared to delaying treatment until the individual progresses to F3. Earlier 
treatment with TPR should be considered as an efficient choice by the French 
health care system based on its estimated incremental cost-effectiveness ratio 
of € 37,197/QALY gained.
